Metal Ion-Responsive Nanocarrier Derived from Phosphonated Calix[4]

Total Page:16

File Type:pdf, Size:1020Kb

Metal Ion-Responsive Nanocarrier Derived from Phosphonated Calix[4] Li et al. J Nanobiotechnol (2020) 18:61 https://doi.org/10.1186/s12951-020-00616-3 Journal of Nanobiotechnology RESEARCH Open Access Metal ion-responsive nanocarrier derived from phosphonated calix[4]arenes for delivering dauricine specifcally to sites of brain injury in a mouse model of intracerebral hemorrhage Mingxin Li1,2, Guohao Liu1,5, Kaixuan Wang1,2, Lingfeng Wang1,2, Xiang Fu6, Lee Yong Lim4, Wei Chen1,2* and Jingxin Mo1,3* Abstract Primary intracerebral hemorrhage (ICH) is a leading cause of long-term disability and death worldwide. Drug delivery vehicles to treat ICH are less than satisfactory because of their short circulation lives, lack of specifc targeting to the 2 hemorrhagic site, and poor control of drug release. To exploit the fact that metal ions such as Fe + are more abundant in peri-hematomal tissue than in healthy tissue because of red blood cell lysis, we developed a metal ion-responsive nanocarrier based on a phosphonated calix[4]arene derivative in order to deliver the neuroprotective agent dauricine (DRC) specifcally to sites of primary and secondary brain injury. The potential of the dauricine-loaded nanocarriers for ICH therapy was systematically evaluated in vitro and in mouse models of autologous whole blood double infusion. The nanocarriers signifcantly reduced brain water content, restored blood-brain barrier integrity and attenuated neurological defcits by inhibiting the activation of glial cells, infltration by neutrophils as well as production of pro- infammatory factors (IL-1β, IL-6, TNF-α) and matrix-metalloprotease-9. These results suggest that our dauricine-loaded nanocarriers can improve neurological outcomes in an animal model of ICH by reducing infammatory injury and inhibiting apoptosis and ferroptosis. Keywords: Intracerebral hemorrhage, Dauricine, Phosphonated calix[4]arene derivative, Targeted delivery, Apoptosis, Ferroptosis Introduction stress and infammatory injury [2]. Much secondary Primary intracerebral hemorrhage (ICH) is the most injury arises from neuroinfammation: hematoma acti- devastating type of stroke [1]. It afects 2 million people vates glial cells, which disrupt the blood-brain barrier, worldwide each year and is associated with high disabil- allowing infltration by peripheral infammatory cells that ity and mortality rates, which have not changed substan- produce abundant cytokines, which in turn stimulate tially for decades. Individuals who sufer ICH have poor neuronal apoptosis and impair neurological function [3, prognosis mainly because of secondary brain injuries 4]. Another major cause of secondary injury is ferroptosis after the stroke, including hematoma toxicity, oxidative due to the abundant free iron released from lysed eryth- rocytes in stroke-injured brain tissue [5, 6]. Te complex- ity of ICH helps explain why no specifc treatment exists, *Correspondence: [email protected]; [email protected] despite the burden it places on health systems worldwide. 1 Clinical Research Center for Neurological Diseases of Guangxi Province, The Afliated Hospital of Guilin Medical University, Guilin 541001, China A neuroprotective agent that may help mitigate sec- Full list of author information is available at the end of the article ondary stroke injury is the isoquinoline alkaloid dauricine © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Li et al. J Nanobiotechnol (2020) 18:61 Page 2 of 19 (DRC), isolated from the Chinese herbal medicine Rhi- down-regulating Bax expression, thereby inhibiting neu- zoma Menispermi (Scheme 1) [7]. DRC can protect the ronal apoptosis, as well as by stimulating IRE-1/XBP-1 brain from ischemic damage by up-regulating Bcl-2 and signaling and down-regulating caspase-3, which relieves Scheme 1 Schematic of the composition and activating environment of metal ion-responsive nanocarriers based on a phosphonated calix[4]arene 2 derivative loaded with the neuroprotective agent dauricine. The micelles release dauricine in response to abundant Fe + at sites of primary and secondary brain injury. The present study was carried out in a mouse model of ICH Li et al. J Nanobiotechnol (2020) 18:61 Page 3 of 19 endoplasmic reticulum stress [8]. However, DRC on its medium, DMEM) supplemented with 10% fetal bovine own shows poor oral absorption, high rate of metabolism serum (FBS; Gibco, Invitrogen, Shanghai, China) and rapid systemic elimination, which means its actual Cultures were maintained in a humidifed 5% CO 2 concentration at hemorrhagic sites is very low [9]. atmosphere. We hypothesized that we could couple DRC with an appropriate carrier that would be responsive to metal Animals and groups ions such as Fe2+ that are more abundant at hematoma Animal protocols were approved by the Department of sites than in normal tissue. As a drug delivery system, we Laboratory Animal Research at Guilin Medical Univer- focused on the calixarene macrocyle and its derivatives, sity (License No. YXLL-2017-167) in compliance with the which have antiviral, antibacterial, antifungal, antituber- Principles of Laboratory Animal Care (People’s Republic cular, anticancer, and anti-oxidant activities [10–13]. We of China). Adult male C57BL/6 mice weighing 20 to 28 g have shown that a p-methylenebisphosphonic calix[4] were used in this study. Mice were maintained at a con- arene derivative can assemble into micelles to form stant ambient temperature (22 ± 1 °C) on a 12-h light/ host-guest complexes with small molecules in the cav- dark cycle. Mice were randomly divided into the follow- ity, such as the drug carboplatin [14, 15]. Furthermore, ing fve groups based on random numbers generated calixarene derivatives can form host–guest complexes using SPSS (IBM, Chicago, IL, USA). Te sham group 2+ 2+ with free metal ions such as Cu and Fe , in some cases (n = 24, of which 24 survived) was subjected to mock with metal selectivity [16–19]. We envisioned that using surgery (craniotomy without blood infusion) and treated calixarene derivatives loaded with DRC could synergisti- with 0.1 mL 0.9% saline. Te vehicle group (n = 26, of cally treat ICH by binding selectively to metal ions and which 21 survived) was subjected to ICH surgery, then by releasing DRC selectively at hemorrhagic sites. In treated with 0.9% saline. Te DRC group (n = 24, of which the present study, we designed O-dodecyl p-methylen- 21 survived) was subjected to ICH surgery, then immedi- ebisphosphonic calix[4]arene micelles containing DRC ately treated with 10 mg/kg DRC (Sigma, purity ≥ 95%, (hereafter referred to as DPM) and explored their anti- Fig. 1) via tail vain injection. Te drug was dissolved in infammatory and neuroprotective efects in a mouse 0.05 mL 20.0% (v/v) HCl, then neutralized with NaOH model of ICH (Scheme 1). (Sigma, USA, purity ≥ 99.0%). Te PM group (n = 24, of which 20 survived) was subjected to ICH surgery, then Materials and methods treated with 90 mg/kg empty p-PCa4C12 micelles (PM). Reagents Te DPM group (n = 24, of which 22 survived) was sub- All reagents, solvents, chemicals and plastic cell culture jected to ICH surgery, then treated with 100 mg/kg dau- supplies were obtained from Sigma-Aldrich (St. Louis, ricine-loaded p-PCa4C12 micelles (DPM, equivalent to MO, USA) or Fisher (Pittsburgh, PA, USA) unless oth- 10.1 mg/kg DRC). erwise mentioned. Annexin V-FITC/PI Apoptosis Kits were purchased from Lianke Technology (Hangzhou, Fabrication of PM and DPM China). Matrigel® Basement Membrane Matrix was DPM were fabricated by a thin-flm hydration method. In obtained from Corning (NY, USA). Ammonium ferrous brief, 100 mg of p-PCa4C12 and 30 mg of DRC were dis- sulfate was ordered from Macklin (Shanghai, China). solved in 50 mL of chloroform in a 150-mL round-bot- ROS Assay Kit was obtained from Beyotime (Shanghai, tom fask. Te fask was attached to a rotary evaporator China). DRC was obtained from Aladdin Chemical Rea- (BUCHI, Switzerland) to get rid of chloroform overnight gent Co., Ltd (Shanghai, China). Paraformaldehyde (4%) in a 37 °C water bath. Te resultant thin flm was rehy- was purchased from Guangzhou Ruishu Biotechnol- drated at 37 °C for half an hour in 20 mL of deionized ogy Co., Ltd (Guangzhou, China). Ultrapure deionized water and then sonicated (probe sonicator, 50% strength; water was obtained from a Millipore system (resistiv- Q700 of QSonica®, Newtown, CT, USA) for 5 min to ity, 18.2 MΩ cm). Phosphonato calixarene (p-PCa4C12, form DPM. Insoluble material was eliminated using a purity > 95%) was synthesized in our laboratory accord- 0.22-μm flter (Millipore flter), and the fltered DPM ing to published methods with some minor modifca- were freeze-dried and stored at − 20 °C for further exper- tions. Its chemical structure was confrmed by 1H-NMR iments. Te same procedure but without DRC was used (Varian Mercury 400, USA; Additional fle 1: Figure S1). to prepare PM.
Recommended publications
  • United States Patent (19) 11 Patent Number: 5,627,195 Hu 45 Date of Patent: May 6, 1997
    USOO5627195A United States Patent (19) 11 Patent Number: 5,627,195 Hu 45 Date of Patent: May 6, 1997 54 TREATMENT FOR OCULAR Ferrante, et al., Tetrandrine, a Plant Alkaloid, Inhibits the NFLAMMATON Production of Tumour Necrosis Factor-Alpha (Cachectin) by Human Monocytes, Clin, exp. Immunol. 80:232–235 75 Inventor: Shixing Hu, Cambridge, Mass. (1990). Kondo, et al., Inhibitory Effect of Bisbenzylisoquinoline 73) Assignee: Massachusetts Eye and Ear Alkaloids on the Quick Death of Mice Treated with BCG/ Infirmary, Boston, Mass. LPS, Chem. Pharm. bull. 38(10):287-2889 (1990). Ph.D. dissertation of Shixing Hu, Sun Yat-Sen University of 21 Appl. No.: 420,244 Medical Sciences, Guang Zhou, Guang Dong China, 1989. 22 Filed: Apr. 11, 1995 Seow, et al. In Vitro Immunosuppressive Properties of Teh Plant Alkaloid Tetrandrine. Int. Archs Allergy appl. Immun. [51] Int. Cl. ... A61K 31/445 85:410-415 (1988). 52 514/321: 514/912 Rao. et al., Modulation of Lens-Induced Uvetis by Super 58 Field of Search ...................................... 54/321, 912 oxide Dismutase, Opthlalmic Res. 18:41-46 (1986). Abal et al., Clinical Evaluation of Berberine in Mycotic 56 References Cited Infections, Ind. J. Ophthalm. 34:91-2 (1986). FOREIGN PATENT DOCUMENTS Mohan, et al. Berberine: An Indigenous Drug in Experi mental Herpetic Uveitis. Ind.J. Ophthalm. 31:65-68 (1983). 46-21396 6/1971 Japan. Yao Hsueh Tung Pao 1983; 18:31-36 The Natural Sources 3-44323 2/1991 Japan. and Biological Activities of Bisbenzylisoquinoline (BBI) 4–99723 3/1992 Japan. Alkaloids. OTHER PUBLICATIONS Babbar, et al., Effect of Berberine Chloride Eye Drops on Marshall, et al.
    [Show full text]
  • Analytical Reference Standards
    Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation.
    [Show full text]
  • Accepted Version
    Article Metabolomics identifies a biomarker revealing in vivo loss of functional ß-cell mass before diabetes onset LI, Lingzi, et al. Abstract Identification of pre-diabetic individuals with decreased functional ß-cell mass is essential for the prevention of diabetes. However, in vivo detection of early asymptomatic ß-cell defect remains unsuccessful. Metabolomics emerged as a powerful tool in providing read-outs of early disease states before clinical manifestation. We aimed at identifying novel plasma biomarkers for loss of functional ß-cell mass in the asymptomatic pre-diabetic stage. Non-targeted and targeted metabolomics were applied on both lean ß-Phb2-/- mice (ß-cell-specific prohibitin-2 knockout) and obese db/db mice (leptin receptor mutant), two distinct mouse models requiring neither chemical nor diet treatments to induce spontaneous decline of functional ß-cell mass promoting progressive diabetes development. Non-targeted metabolomics on ß-Phb2-/- mice identified 48 and 82 significantly affected metabolites in liver and plasma, respectively. Machine learning analysis pointed to deoxyhexose sugars consistently reduced at the asymptomatic pre-diabetic stage, including in db/db mice, showing strong correlation with the gradual loss of ß-cells. [...] Reference LI, Lingzi, et al. Metabolomics identifies a biomarker revealing in vivo loss of functional ß-cell mass before diabetes onset. Diabetes, 2019, vol. 68, no. 12, p. 2272-2286 PMID : 31537525 DOI : 10.2337/db19-0131 Available at: http://archive-ouverte.unige.ch/unige:126176
    [Show full text]
  • Methoxy-3-Veratryl-5,6-Dihydrobenzoglyoxalocoline T
    HFTEROCYCLES. Vol 30, No I, 1990 PAPERS OF PROFESSOR TETSUJI KAMETANI 1 Studies on the Synthesis of Emetine and Related Compounds. VI. A Syn thesis of 4'. 5'-Methylenedioxy-6-[B-6". 7"-methylenedioxy-3"-methyl-py- tetrahydroisoquinolyl-I"] -ethyl]-4-methyl-3,4,5,6,7, B-hexahydro- ( 1 2 : 1.2-benzoquinolizine) S . Sugasawa and T . Kametani [Yakugaku Zasshi. 65, 372 - 373 (194511 2 Syntheses of Imidazoisoquinoline Derivatives. I. Synthesis of 9.10- Dimethoxy- 3- (p-aminophenyl)- -5.6-dihydrohenzoglyoxalocoline T . Kametani and H. Iida [ Yakugaku Zasshi, 70, 258 - 261 (19501 1 3 Syntheses of Imidazoisoquinoline Derivatives. 11. Synthesis of 9.10-Di- methoxy-3-veratryl-5,6-dihydrobenzoglyoxalocoline T. Kametani and H. Iwakata [ Yakugaku Zasshi, 70, 261 - 263 (1950) 1 4 Syntheses of Imidazoisoquinoline Derivatives. 111. Synthesis of 9.10-Di- methoxy- 3-safryl- 5.6-dihydrobenzoglyoxalocoline T . Kametani and H. Iwakata [Yakugaku Zasshi, 70. 263 - 265 (195011 5 Syntheses of Papaverine Derivatives. I. Synthesis of 1-(3'-Methoxy-4'- hydroxyphenyl) -3-methyl-6.7-methylenedioxyisoquinoline T. Kametani [ Yakugaku Zasshi, 71. 322 - 324 (1951) I 6 Syntheses of Imidazoisoquinoline Derivatives. IV. Syntheses of 9,lO- Methylenedioxy- 3- (4'-nitrophenyl) - 5-methyl- 5.6-dihydrobenzoglyoxalocoline. 9,lO-Methylenedioxy-3- (3', 4'-dimethoxypheny1)-5-methylbenzoglyoxalocoline and 9,lO-Methylenedioxy-3-( 3'. 4'-methylenedioxyphenyl]-5-methyl-5,6- dihydrobenzoglyo::alocoline T. Kametani, H. Iida, and H. Iwakata [ Yakugaku Zasshi. 71. 325- 329 (195111 Studies on the Syntheses of Aminoisoquinoline Derivatives. I. Saponification of Benzyl 1-Phenyl-6.7-dimethoxyisoquinoly1-3-carbamate T. Kametani [ Yakugaku Zasshi, 71. 329 - 331 (1951) I Studies on the Syntheses of Aminoisoquinoline Derivatives.
    [Show full text]
  • UC Riverside UC Riverside Previously Published Works
    UC Riverside UC Riverside Previously Published Works Title The biology and total syntheses of bisbenzylisoquinoline alkaloids. Permalink https://escholarship.org/uc/item/67s758hb Journal Organic & biomolecular chemistry, 19(35) ISSN 1477-0520 Authors Nguyen, Viviene K Kou, Kevin GM Publication Date 2021-09-15 DOI 10.1039/d1ob00812a Peer reviewed eScholarship.org Powered by the California Digital Library University of California Please do not adjust margins REVIEW The biology and total syntheses of bisbenzylisoquinoline alkaloids Viviene K. Nguyen, Kevin. G. M. Kou* Received 00th January 20xx, Accepted 00th January 20xx DOI: 10.1039/x0xx00000x This mini-review provides a concise overview of the biosynthetic pathway and pharmacology of the bisbenzylisoquinoline alkaloid (bisBIA) natural poducts. Additional emphasis is given to the methodologies in the total syntheses of both the simpler acyclic diaryl ether dimers and their macrocyclic counterparts bearing two diaryl ether linkages. 1. Introduction and classification The benzylisoquinoline alkaloids (BIAs) represent a family of over 2500 plant natural products that have been used for centuries as analgesics and wound disinfectants.1 Some of the active and biosynthetically-related members, have been exploited in modern medicine, for example, morphine for pain, 2 colchicine for gout, and noscapine for cough and cancer. In Figure 1. Coclaurine (1 and 2) and/or reticuline (3) are the recent years, the pursuit of bisbenzylisoquinoline alkaloids biosynthetic building blocks of the majority of bisBIAs. (bisBIAs), molecules comprising two BIA motifs, is gaining traction. Isolated from the Berberidaceae, Ranunculaceae, their botanical sources as well as spectral and physical data.1-8 Lauraceae and Menispermaceae plant families, these This review highlights the biosynthesis and medicinal compounds can modulate diverse biological functions.3,4 With implications of bisBIAs.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,949,521 B2 Chu Et Al
    USOO6949521B2 (12) United States Patent (10) Patent No.: US 6,949,521 B2 Chu et al. (45) Date of Patent: Sep. 27, 2005 (54) THERAPEUTICAZIDE COMPOUNDS Adamiak et al., “Synthesis of 6-Substituted Purines and ribonucleosides with N-(6-Purinyl)pyridinium Salts.” (75) Inventors: Chung K. Chu, Athens, GA (US); Angewandte Chemie, Intl. Ed., 24(12):1054–1055 (Dec., Lakshmi P. Kotra, Detroit, MI (US); 1985). Konstantine Manouilov, Omaha, NE Agarwal, R.P. et al., “Clinical Pharmacology of 9-3-D-Ara (US); Jinfa Du, Irvine, CA (US); binofuranosyladenine in Combination with 2'-Deoxycofor Raymond Schinazi, Decatur, GA (US) mycin,” Cancer Res., 42(9):3884–3886 (Sep., 1982). Anderson, B.D. et al., “Uptake Kinetics of 2',3'-Dideoxyi (73) Assignees: The University of Georgia Research nosine into Brain and Cerebrospinal Fluid of Rats: Intrave Foundation, Inc., Athens, GA (US); nous Infusion Studies,” J. Pharmacol. Exp. Ther., (1990) Emory University, Atlanta, GA (US) 253(1): 113–118. Andrei, G. et al., “Comparative Activity of Various Com (*) Notice: Subject to any disclaimer, the term of this pounds Against Clinical Strains of Herpes Simplex Virus,” patent is extended or adjusted under 35 Eur: J. Clin. Microbiol. Infect. Diseases, (1992) U.S.C. 154(b) by 396 days. 11(2):143–151. Balzarini, J. And DeClercq, E., “The Antiviral Activity of (21) Appl. No.: 09/849,870 9-B-D Arabinofuranosyladenine is Enhanced by the 2',3'-Dideoxyriboside, the 2',3'-Didehydro-2',3'-Dideox (22) Filed: May 4, 2001 yriboside and the 3'-Azido-2',3'-Dideoxyriboside of (65) Prior Publication Data 2,6-Diaminopurine,” Biochem.
    [Show full text]
  • Novel Chemical Tools for the Modulation of Two Pore Channel 2
    Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig‐Maximilians‐Universität München NOVEL CHEMICAL TOOLS FOR THE MODULATION OF TWO PORE CHANNEL 2 Susanne Daniela Gerndt aus Schweinfurt 2020 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Franz Bracher betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. München, den 29.06.2020 ____________________________ Susanne Daniela Gerndt Dissertation eingereicht am: 01.07.2020 1. Gutachter: Prof. Dr. Franz Bracher 2. Gutachter: Prof. Dr. Dr. Christian Grimm Mündliche Prüfung am 27.07.2020 Danksagung An dieser Stelle möchte ich mich ganz herzlich bei allen bedanken, die diese Arbeit durch viele große und kleine Beiträge erst ermöglicht haben: Allen voran Herrn Prof. Dr. Franz Bracher für dieses interessante und abwechslungsreiche Thema und seine stets großzügige Unterstützung und Förderung während der vergangenen Jahre. Ebenso bedanken möchte ich mich bei den Mitgliedern der Prüfungskommission, vor allem bei Prof. Dr. Dr. Christian Grimm, nicht nur für die freundliche Übernahme des Koreferats, sondern auch für die Möglichkeit mich in ein mir fachfremdes Thema einzuarbeiten und viel Neues zu lernen. Weiter möchte ich auch meinen Kooperationspartnern danken, sei es in München Frau Prof. Dr. Angelika Vollmar, in Leipzig Prof. Dr. Michael Schaefer oder anderswo. Bei den Mitarbeitern der Analytikabteilung der Chemie und Pharmazie bedanke ich mich auch recht herzlich für die zahlreichen Messungen und die Hilfe bei analytischen Fragestellungen. Einen herzlichen Dank richte ich auch an die Arbeitsgruppen Biel, Grimm und Schaefer, die mich im Rahmen gemeinsamer Kooperationen freundlich aufgenommen und unterstützt haben.
    [Show full text]
  • Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N
    Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N. Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE by Ronald N. Kostoff a, Yi Zhang b , Jing Ma c, Alan L. Porter d, Henry. A. Buchtel e (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Post-Doctoral Researcher, Faculty of Engineering and Information Technology, University of Technology Sydney, Australia (c) Assistant Professor, College of Management, Shenzhen University, China (d) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (e) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Information Technology; Adverse Events; Risk Factors; Contributing Factors CITATION TO MONOGRAPH Kostoff RN, Zhang Y, Ma J, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's Disease. Georgia Institute of Technology. 2017. PDF. < https://smartech.gatech.edu/handle/1853/56646 > 1 Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N. Kostoff et al COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2017 by Ronald N. Kostoff, Yi Zhang , Jing Ma, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2017 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology, the University of Michigan, Shenzhen University, or the University of Technology Sydney.
    [Show full text]
  • Permanently Charged Sodium and Calcium Channel Blockers As Anti-Inflammatory Agents
    (19) TZZ ¥Z¥_T (11) EP 2 995 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.03.2016 Bulletin 2016/11 A61K 31/165 (2006.01) A61K 31/277 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) Application number: 15002768.8 A61P 11/00 A61P 13/00 A61P 17/00 (2006.01) A61P 1/00 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.07.2010 A61P 27/02 A61P 29/00 A61P 37/08 (2006.01) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WOOLF, Clifford, J. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newton, MA 02458 (US) PL PT RO SE SI SK SM TR • BEAN, Bruce, P. Waban, MA 02468 (US) (30) Priority: 10.07.2009 US 224512 P (74) Representative: Lahrtz, Fritz (62) Document number(s) of the earlier application(s) in Isenbruck Bösl Hörschler LLP accordance with Art. 76 EPC: Patentanwälte 10797919.7 / 2 451 944 Prinzregentenstrasse 68 81675 München (DE) (71) Applicants: • President and Fellows of Harvard College Remarks: Cambridge, MA 02138 (US) This application was filed on 25-09-2015 as a • THE GENERAL HOSPITAL CORPORATION divisional application to the application mentioned Boston, MA 02114 (US) under INID code 62. • CHILDREN’S MEDICAL CENTER CORPORATION Boston, Massachusetts 02115 (US) (54) PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS (57) The present invention relates to a composition or a kit comprising N-methyl etidocaine for use in a method for treating neurogenic inflammation in a patient, wherein the kit further comprises instructions for use.
    [Show full text]
  • Namenverzeichnis. Index of Names. Index Des Auteurs
    Namenverzeichnis. Index of Names. Index des Auteurs. Kursiv gedruckte Seitenzahlen beziehen sich auf Literaturverzeichnisse. Page numbers printed in italic refer to References. Les chiffres en italique indiquent les pages de bibliographie. ABISCH, E. 107, 109, I38. ANDERSSON, C. O. 74, 76, 86. ABRAHAMS, P. 159, 175, 176, I94. ANDO, M. 118, 119, I42. ACHENBACH, H. 26, 27, 44, 45, 49, 50, ANDRES, W. W. 131, I44. 86, 97. ANGYAL, S. J. 154, 175, 180, 186, I92. ACKERMANN, D. 18o, I92. ANNER, G. III, I43. ADAMS, R. 189, I92, 332, 335, 336, 340, ANSELL, G. B. 154, 180, I92. 344, 345, 348, 358, 36o, 363, 365, 367, ANTONACCIO, L. D. 18, 27, 29, 37, 38, 369--371, 375, 379--381 , 383--386, 86, 90, 9I. 390, 391, 393, 396, 397, 40 3. AOKI, T. 125, 130, I44. ADELBERG, A. E. 364, 391, 405. APGAR, J. 412, 413, 435· ADHIKARI, S. K. 181, 184, I92. APLIN, R. T. 63, 65, 9I, 93, 238, 241, 270, ADKINS, A. L. 307, 309, 324. 275· ADLER, E. 321, 32I, 326. ApPEL, H. H. I92. AGRANOFF, B. W. 158, 176, 177, I92, I93, ApSIMON, J. W. 237, 238, 273, 275· I95· ARENDARUK, A. P. 335, 374, 382, 386, AGUAYO BRISSOLESE, J. 18, 27, 31, 42, 388, 391, 397· 9I , 92 . ARESHKINA, L. VA. 374, 397. AHLUWALIA, V. K. 261, 275. ARGOUDELIS, A. D. 183, I92, 203. AHMANN, C. F. 381, 395. ARIGONI, D. 116, 129, I38. AHMED, Q. A. 181, 202. ARISON, B. 318, 320, 328. AHOND, A. 236, 272, 275. ARNDT, R. R. 40, 55, 86, 94· AHUJA, J.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0172429 A1 Woolf Et Al
    US 2012O172429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0172429 A1 Woolf et al. (43) Pub. Date: Jul. 5, 2012 (54) PERMANENTLY CHARGED SODUMAND Publication Classification CALCUMI CHANNEL BLOCKERS AS ANT (51) Int. Cl. NFLAMMLATORY AGENTS A 6LX 3L/277 (2006.01) C07C 237/14 (2006.01) (76) Inventors: Clifford J. Woolf, Newton, MA C07C 255/33 (2006.01) (US); Bruce P. Bean, Waban, MA A6IP 25/00 (2006.01) (US) A6IP 29/00 (2006.01) A6IP II/06 (2006.01) A6IP II/IO (2006.01) (21) Appl. No.: 13/382,834 A6IP 9/02 (2006.01) A6IP 700 (2006.01) (22) PCT Fled: Jul. 9, 2010 A6IPI/00 (2006.01) A6IPI3/02 (2006.01) (86) PCT NO.: PCT/US 10/41537 A6IP 25/06 (2006.01) A6IP 7/06 (2006.01) S371 (c)(1), A6IP II/02 (2006.01) (2), (4) Date: Mar. 26, 2012 A6II 3/16 (2006.01) (52) U.S. Cl. .......... 514/523: 514/626:564/194; 558/408 Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 61/224,512, filed on Jul. The invention provides compounds, compositions, methods, 10, 2009. and kits for the treatment of neurogenic inflammation. Patent Application Publication US 2012/0172429 A1 7Z089||Z0897ZZOZ7Z euu||(SunO?) 3.Infi!--| Patent Application Publication Jul. 5, 2012 Sheet 2 of 2 US 2012/0172429 A1 Figure 2 1 uM Capsaicin - Before - After (3 min Wash) 1 uM Capsaicin +300 uMN-methyl-verapamil After (3 min Wash) US 2012/0172429 A1 Jul. 5, 2012 PERMANENTLY CHARGED SODUMAND of a compound that is capable of entering a nociceptor CALCUMI CHANNEL BLOCKERS AS ANT through a channel-forming receptor present in the nociceptor NFLAMMLATORY AGENTS when the receptor is activated and inhibiting a Voltage-gated ion channel present in the nociceptor, wherein the compound CROSS-REFERENCE TO RELATED does not substantially inhibit said channel when applied to the APPLICATIONS extracellular face of the channel and when the receptor is not 0001.
    [Show full text]
  • Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’S Disease
    molecules Review Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease Lucie Cahlíková 1,* , Rudolf Vrabec 2, Filip Pidaný 1, Rozálie Peˇrinová 1, Negar Maafi 1 , Abdullah Al Mamun 1 , Aneta Ritomská 1, Viriyanata Wijaya 1 and Gerald Blunden 3 1 ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic; [email protected] (F.P.); [email protected] (R.P.); [email protected] (N.M.); [email protected] (A.A.M.); [email protected] (A.R.); [email protected] (V.W.) 2 Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic; [email protected] 3 School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire P01 2DT, UK; [email protected] * Correspondence: [email protected]; Tel.: +420-495-067-311 Abstract: Alzheimer’s disease (AD) is a progressive age-related neurodegenerative disease recog- nized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is Citation: Cahlíková, L.; Vrabec, R.; urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be Pidaný, F.; Peˇrinová,R.; Maafi, N.; promising candidates for use in the treatment of AD.
    [Show full text]